CY1117268T1 - Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου - Google Patents
Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινουInfo
- Publication number
- CY1117268T1 CY1117268T1 CY20161100189T CY161100189T CY1117268T1 CY 1117268 T1 CY1117268 T1 CY 1117268T1 CY 20161100189 T CY20161100189 T CY 20161100189T CY 161100189 T CY161100189 T CY 161100189T CY 1117268 T1 CY1117268 T1 CY 1117268T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nurses
- periodical
- compounds
- supporting
- cancer factor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010060860 Neurological symptom Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010015935 | 2010-01-27 | ||
| EP11705047.6A EP2528598B1 (en) | 2010-01-27 | 2011-01-26 | Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117268T1 true CY1117268T1 (el) | 2017-04-26 |
Family
ID=43770309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100189T CY1117268T1 (el) | 2010-01-27 | 2016-03-04 | Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου |
Country Status (41)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2602810C2 (ru) * | 2012-04-27 | 2016-11-20 | Ниппон Дзоки Фармасьютикал Ко., Лтд. | Производное транс-2-деценовой кислоты и содержащее его лекарственное средство |
| BR112016013896A2 (pt) * | 2013-12-17 | 2017-10-10 | Genentech Inc | métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2 |
| ES2772703T3 (es) | 2015-05-08 | 2020-07-08 | Takeda Pharmaceuticals Co | Compuestos cíclicos |
| CN116327953A (zh) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| RU2742337C2 (ru) * | 2016-09-09 | 2021-02-04 | Такеда Фармасьютикал Компани Лимитед | Циклическое соединение |
| CN111465389B (zh) * | 2017-09-07 | 2022-06-21 | 深圳信立泰药业股份有限公司 | 多西他赛共缀物的药物组合物及制备方法 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
| EP0252146B1 (en) | 1986-01-09 | 1994-05-25 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| WO1988005083A1 (en) | 1986-12-24 | 1988-07-14 | Whitehead Institute For Biomedical Research | Method of inducible gene expression |
| WO1989007614A1 (en) | 1988-02-12 | 1989-08-24 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| CA1340174C (en) | 1988-03-01 | 1998-12-08 | Patrick A. Baeuerle | Activation of nf-kb precursor |
| US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| DE69027026T2 (de) | 1989-03-31 | 1996-09-26 | Childrens Medical Center | Behandlung von aids, dementia, myelopathie und blindheit |
| US5158883A (en) | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
| US5059712A (en) | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
| WO1992003137A1 (en) | 1990-08-23 | 1992-03-05 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
| WO1992017168A1 (en) | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
| US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| EP0581856B1 (en) | 1991-04-19 | 1999-07-14 | The Children's Medical Center Corporation | Method of preventing nmda receptor complex-mediated neuronal damage |
| US6071876A (en) | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
| KR19990022369A (ko) * | 1995-06-07 | 1999-03-25 | 스테판 이반스-프레크 | 어뎁터 단백질/티로신 카이나제 상호작용을 방해하는 조성물과그 방법 |
| US20020052019A1 (en) | 1997-11-13 | 2002-05-02 | Genentech Inc | Human toll homologue |
| WO2001090151A2 (en) | 2000-05-25 | 2001-11-29 | Schering Corporation | Human receptor proteins; related reagents and methods |
| US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
| IL135345A0 (en) | 1997-10-17 | 2001-05-20 | Genentech Inc | Human toll homologues |
| ZA989147B (en) | 1997-10-17 | 2000-04-07 | Genentech Inc | Human toll homologues. |
| US20080275104A1 (en) | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| EP1034266A1 (en) | 1997-11-25 | 2000-09-13 | Princeton University | Method for preparing adenovirus vectors, vectors so prepared, and uses thereof |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US20040072138A1 (en) | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
| KR100779889B1 (ko) | 1998-03-09 | 2007-11-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 시클로알켄 유도체, 그의 제조 방법 및 용도 |
| CA2380990A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | Substituted aromatic-ring compounds, process for producing the same, and use |
| SE9903930D0 (sv) * | 1999-10-29 | 1999-10-29 | Astra Pharma Inc | Novel compounds and a novel process for their preparation |
| EP1254659B1 (en) | 2000-02-04 | 2006-11-15 | Takeda Pharmaceutical Company Limited | Stable emulsion compositions |
| CA2418224C (en) | 2000-08-10 | 2010-02-09 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
| WO2002032859A1 (en) | 2000-10-18 | 2002-04-25 | Takeda Chemical Industries, Ltd. | Process for preparation of optically active sulfonamides and intermediates for their synthesis |
| CA2398613C (en) | 2000-11-30 | 2006-09-12 | Tokuyama Corporation | Substrate and production method therefor |
| CA2431206C (en) | 2000-12-08 | 2009-09-01 | Takeda Chemical Industries, Ltd. | Combination drugs containing anti-sepsis cycloalkene compound |
| WO2003013513A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Stable emulsion composition |
| AU2003236290A1 (en) | 2002-04-08 | 2003-10-20 | Takeda Chemical Industries, Ltd. | Severe sepsis preventive therapeutic agent |
| US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20040259790A1 (en) | 2003-01-30 | 2004-12-23 | Bali Pulendran | Methods for identifying and administering agents that bias the immune response via dendritic cells |
| EP1599726A4 (en) | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
| WO2004087049A2 (en) | 2003-03-25 | 2004-10-14 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
| US20050059072A1 (en) | 2003-09-17 | 2005-03-17 | 3M Innovative Properties Company | Selective modulation of TLR gene expression |
| WO2005084180A2 (en) | 2003-12-19 | 2005-09-15 | University Of Cincinnati | Polyamides and polyamide complexes for delivery of oligonucleotide decoys |
| MY147790A (en) | 2005-04-28 | 2013-01-31 | Takeda Pharmaceutical | Stable emulsion composition |
| BRPI0611079A2 (pt) | 2005-06-03 | 2010-08-03 | Ono Pharmaceutical Co | agentes para a regeneração e/ou proteção de nervos |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| US20090175835A1 (en) | 2006-02-07 | 2009-07-09 | Korea Institute Of Radiological & Medical Sciences | Composition for treating damage of central or peripheral nerve system |
| ATE524732T1 (de) | 2006-02-23 | 2011-09-15 | Univ Yale | Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg |
| US7943588B2 (en) | 2006-03-28 | 2011-05-17 | Trustees Of Dartmouth College | Method for preventing or treating neuropathic pain |
| EP1997902B1 (en) | 2006-03-30 | 2013-09-18 | Hiroshima University | Screening method |
| EP2018872A4 (en) * | 2006-04-20 | 2010-06-09 | Takeda Pharmaceutical | PHARMACEUTICAL PRODUCT |
| EP2018855A1 (en) | 2006-05-15 | 2009-01-28 | Takeda Pharmaceutical Company Limited | Pharmaceutical agent |
| JPWO2008004673A1 (ja) | 2006-07-07 | 2009-12-10 | 武田薬品工業株式会社 | シクロアルケン誘導体、その製造法および用途 |
| EP1882687A1 (en) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same |
| US20080227846A1 (en) | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| WO2009059050A2 (en) | 2007-10-30 | 2009-05-07 | The Regents Of The University Of Colorado | Tlr modulators and methods for using the same |
| JP2011513483A (ja) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| JP5238381B2 (ja) | 2008-07-07 | 2013-07-17 | スタンレー電気株式会社 | 照明用車両用灯具 |
| AU2010298157A1 (en) | 2009-09-23 | 2012-04-12 | The Regents Of The University Of Colorado, A Body Corporate | Toll-like receptor modulators and uses thereof |
-
2011
- 2011-01-26 PL PL11705047T patent/PL2528598T3/pl unknown
- 2011-01-26 NZ NZ601635A patent/NZ601635A/xx not_active IP Right Cessation
- 2011-01-26 EP EP11705047.6A patent/EP2528598B1/en active Active
- 2011-01-26 HR HRP20160165TT patent/HRP20160165T1/hr unknown
- 2011-01-26 CN CN201510072433.2A patent/CN104744321A/zh active Pending
- 2011-01-26 MA MA35162A patent/MA34014B1/fr unknown
- 2011-01-26 TW TW100102774A patent/TWI481401B/zh not_active IP Right Cessation
- 2011-01-26 EA EA201290697A patent/EA201290697A1/ru unknown
- 2011-01-26 SI SI201130755T patent/SI2528598T1/sl unknown
- 2011-01-26 WO PCT/JP2011/052077 patent/WO2011093512A1/en not_active Ceased
- 2011-01-26 UA UAA201210137A patent/UA109540C2/uk unknown
- 2011-01-26 UY UY0001033203A patent/UY33203A/es not_active Application Discontinuation
- 2011-01-26 ME MEP-2016-31A patent/ME02364B/me unknown
- 2011-01-26 SG SG2012051967A patent/SG182522A1/en unknown
- 2011-01-26 BR BR112012018434A patent/BR112012018434A2/pt not_active IP Right Cessation
- 2011-01-26 CA CA2788150A patent/CA2788150C/en not_active Expired - Fee Related
- 2011-01-26 ES ES11705047.6T patent/ES2560215T3/es active Active
- 2011-01-26 KR KR1020127021846A patent/KR20120118044A/ko not_active Abandoned
- 2011-01-26 HU HUE11705047A patent/HUE027310T2/en unknown
- 2011-01-26 AU AU2011211294A patent/AU2011211294B2/en not_active Ceased
- 2011-01-26 PT PT117050476T patent/PT2528598E/pt unknown
- 2011-01-26 JP JP2012533416A patent/JP6131046B2/ja active Active
- 2011-01-26 CN CN201180015681.3A patent/CN102821763B/zh not_active Expired - Fee Related
- 2011-01-26 MY MYPI2012003414A patent/MY163936A/en unknown
- 2011-01-26 GE GEAP201112845A patent/GEP20166441B/en unknown
- 2011-01-26 US US13/574,848 patent/US20130046000A1/en not_active Abandoned
- 2011-01-26 DK DK11705047.6T patent/DK2528598T3/en active
- 2011-01-26 PE PE2012001062A patent/PE20121694A1/es not_active Application Discontinuation
- 2011-01-26 SG SG10201503402XA patent/SG10201503402XA/en unknown
- 2011-01-26 AR ARP110100247A patent/AR080024A1/es unknown
- 2011-01-26 RS RS20160076A patent/RS54591B1/sr unknown
- 2011-01-26 PH PH1/2012/501538A patent/PH12012501538A1/en unknown
- 2011-01-26 MX MX2012008514A patent/MX2012008514A/es not_active Application Discontinuation
-
2012
- 2012-07-17 TN TNP2012000364A patent/TN2012000364A1/en unknown
- 2012-07-23 IL IL221066A patent/IL221066A/en not_active IP Right Cessation
- 2012-07-25 DO DO2012000209A patent/DOP2012000209A/es unknown
- 2012-07-26 CL CL2012002079A patent/CL2012002079A1/es unknown
- 2012-07-27 ZA ZA2012/05681A patent/ZA201205681B/en unknown
- 2012-08-07 CR CR20120412A patent/CR20120412A/es unknown
- 2012-08-17 CO CO12140288A patent/CO6592110A2/es not_active Application Discontinuation
- 2012-08-27 EC ECSP12012126 patent/ECSP12012126A/es unknown
-
2013
- 2013-08-20 US US13/971,159 patent/US8901171B2/en not_active Expired - Fee Related
-
2014
- 2014-10-28 US US14/525,576 patent/US20150051256A1/en not_active Abandoned
-
2015
- 2015-04-02 US US14/676,947 patent/US20150203464A1/en not_active Abandoned
-
2016
- 2016-02-19 US US15/047,965 patent/US20160166526A1/en not_active Abandoned
- 2016-03-04 CY CY20161100189T patent/CY1117268T1/el unknown
- 2016-03-18 JP JP2016056186A patent/JP2016175903A/ja active Pending
- 2016-04-12 SM SM201600103T patent/SMT201600103B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117268T1 (el) | Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου | |
| CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
| CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| IL235607A0 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| HRP20220897T8 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| LT3447061T (lt) | Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui | |
| BR112013025415A2 (pt) | métodos para aumentar eficácia de terapia de câncer de folr1 | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| BR112014013526A2 (pt) | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados | |
| CR20150120A (es) | Nuevos derivados bicíclicos | |
| MX376058B (es) | Uso de peptidos glp-1 de accion prolongada. | |
| UY34013A (es) | ?compuestos de cromenona con actividad anti-tumoral?. | |
| CY1120094T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| HUE045314T2 (hu) | Kombinációs terápia rák kezelésére | |
| BR112015006705A2 (pt) | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| EA201590863A1 (ru) | Пролекарства с минимальной токсичностью | |
| CL2013003324A1 (es) | Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón. | |
| CY1117541T1 (el) | Αντικαρκινικες στεροειδεις λακτονες μη κορεσμενες στη θεση 7(8) | |
| UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
| UY31646A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico | |
| JO3337B1 (ar) | تركيبات صيدلية تشمل أليسبوريفير | |
| EA201401045A1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией |